ArticlePharmacoEconomics2011

Updated cost-effectiveness analysis of trastuzumab for early breast cancer: a UK perspective considering duration of benefit, long-term toxicity and pattern of recurrence.

Peter S Hall et al.PubMed ↗Publisher ↗

No numbers read from the abstract.